NYSE - Nasdaq Real Time Price USD

Bausch Health Companies Inc. (BHC)

Compare
7.88
+0.05
+(0.64%)
At close: January 10 at 4:00:01 PM EST
7.77
-0.11
(-1.40%)
After hours: January 10 at 7:24:12 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
9,474,000.00
8,757,000.00
8,124,000.00
8,434,000.00
8,027,000.00
Cost of Revenue
2,760,000.00
2,559,000.00
2,364,000.00
2,394,000.00
2,249,000.00
Gross Profit
6,714,000.00
6,198,000.00
5,760,000.00
6,040,000.00
5,778,000.00
Operating Expense
4,965,000.00
4,598,000.00
4,370,000.00
4,472,000.00
4,496,000.00
Operating Income
1,749,000.00
1,600,000.00
1,390,000.00
1,568,000.00
1,282,000.00
Net Non Operating Interest Income Expense
-1,383,000.00
-1,302,000.00
-1,450,000.00
-1,419,000.00
-1,521,000.00
Other Income Expense
-415,000.00
-688,000.00
-69,000.00
-1,173,000.00
-695,000.00
Pretax Income
-49,000.00
-390,000.00
-129,000.00
-1,024,000.00
-934,000.00
Tax Provision
168,000.00
221,000.00
83,000.00
-87,000.00
-375,000.00
Net Income Common Stockholders
-178,000.00
-592,000.00
-225,000.00
-948,000.00
-560,000.00
Diluted NI Available to Com Stockholders
-178,000.00
-592,000.00
-225,000.00
-948,000.00
-560,000.00
Basic EPS
-0.48
-1.62
-0.62
-2.64
-1.58
Diluted EPS
-0.48
-1.62
-0.62
-2.64
-1.58
Basic Average Shares
367,300.00
365,432.10
362,903.23
359,405.75
355,000.00
Diluted Average Shares
367,300.00
365,432.10
362,903.23
359,405.75
358,200.00
Total Operating Income as Reported
1,350,000.00
963,000.00
454,000.00
450,000.00
676,000.00
Total Expenses
7,725,000.00
7,157,000.00
6,734,000.00
6,866,000.00
6,745,000.00
Net Income from Continuing & Discontinued Operation
-178,000.00
-592,000.00
-225,000.00
-948,000.00
-560,000.00
Normalized Income
174,750.00
-179,800.00
-174,822.80
125,340.82
-49,910.00
Interest Income
31,000.00
26,000.00
14,000.00
7,000.00
13,000.00
Interest Expense
1,414,000.00
1,328,000.00
1,464,000.00
1,426,000.00
1,534,000.00
Net Interest Income
-1,383,000.00
-1,302,000.00
-1,450,000.00
-1,419,000.00
-1,521,000.00
EBIT
1,365,000.00
938,000.00
1,335,000.00
402,000.00
600,000.00
EBITDA
2,654,000.00
2,202,000.00
2,729,000.00
1,954,000.00
2,425,000.00
Reconciled Cost of Revenue
2,571,000.00
2,372,000.00
2,185,000.00
2,217,000.00
2,069,000.00
Reconciled Depreciation
1,289,000.00
1,264,000.00
1,394,000.00
1,552,000.00
1,825,000.00
Net Income from Continuing Operation Net Minority Interest
-178,000.00
-592,000.00
-225,000.00
-948,000.00
-560,000.00
Total Unusual Items Excluding Goodwill
-415,000.00
-687,000.00
-68,000.00
-1,173,000.00
-694,000.00
Total Unusual Items
-415,000.00
-687,000.00
-68,000.00
-1,173,000.00
-694,000.00
Normalized EBITDA
3,069,000.00
2,889,000.00
2,797,000.00
3,127,000.00
3,119,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-62,250.00
-274,800.00
-17,822.80
-99,659.18
-183,910.00
12/31/2020 - 3/29/1994

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PRGO Perrigo Company plc
24.38
-2.67%
 
TEVA Teva Pharmaceutical Industries Limited
20.94
-2.56%
 
AMRX Amneal Pharmaceuticals, Inc.
7.97
-1.12%
 
ELAN Elanco Animal Health Incorporated
11.43
-1.04%
 
ALKS Alkermes plc
28.08
-1.20%
 
OPTN OptiNose, Inc.
5.30
-6.45%
 
VTRS Viatris Inc.
11.67
-2.42%
 
ITCI Intra-Cellular Therapies, Inc.
94.87
+14.91%
 
ACB.TO Aurora Cannabis Inc.
5.95
-6.15%
 
EBS Emergent BioSolutions Inc.
9.88
-2.08%